Patrick Stephen Gallagher - Feb 15, 2023 Form 4/A - Amendment Insider Report for Sensei Biotherapeutics, Inc. (SNSE)

Role
Chief Business Officer
Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Stock symbol
SNSE
Transactions as of
Feb 15, 2023
Transactions value $
$0
Form type
4/A - Amendment
Date filed
3/29/2023, 05:13 PM
Date Of Original Report
Feb 17, 2023
Previous filing
Jun 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNSE Common Stock Award $0 +29.3K $0.00 29.3K Feb 15, 2023 Direct F1, F2
transaction SNSE Common Stock Award $0 +14.2K +48.44% $0.00 43.5K Feb 15, 2023 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNSE Stock Option (Right to Buy) Award $0 +60K $0.00 60K Feb 15, 2023 Common Stock 60K $1.43 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This amendment is being filed solely to correct the number of shares beneficially owned, which the original filing overreported by two shares.
F2 These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs are fully vested.
F3 These shares represent RSUs. Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in four equal annual installments on each of February 15, 2024, February 15, 2025, February 15, 2026 and February 15, 2027, subject to the Reporting Person's continuous service with the Issuer as of each such date.
F4 The option shall vest over a period of four years as follows: 25% of the total number of shares subject to the option shall vest on February 15, 2024, and the remainder will vest 1/48th of total number of shares subject to the option monthly thereafter over the remaining three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.